Avon’s Pink Ribbon Cosmetics Case Carries Make-up And a Message

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 7
Volume 7
Issue 7

NEW YORK--Avon’s Breast Cancer Awareness Crusade is combining health and beauty with the introduction of its newest fundraising product, the Avon Pink Ribbon Cosmetics Case.

 NEW YORK--Avon’s Breast Cancer Awareness Crusade is combining health and beauty with the introduction of its newest fundraising product, the Avon Pink Ribbon Cosmetics Case.

The cosmetics case joins Avon’s other pink ribbon products, including a pin and coffee mug, proceeds of which have helped Avon’s Crusade raise more than $25 million for US nonprofit breast health programs nationwide and contributed to the Avon Worldwide Fund for Women’s Health, a global initiative that is expected to reach the $50 million fundraising mark in 1998.

"The message we are bringing to women this year is: Claim Your Health, Claim Your Beauty," said Joanne Mazurki, director of Avon’s Crusade. "We are reminding women that along with their daily beauty routines, they should be equally diligent about practicing good breast health."

The Cosmetics Case will be available in October at a price of $3.00. To order, contact the nearest Avon Sales Representative or call 1-800-FOR-AVON.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content